UNSPSC 51123901: Alprafenone

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D5H25D039V. European Medicines Agency schedules Alprafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05369MIG. Alprafenone generally arises in the molecular formula C25H35NO4.

UNSPSC 51123901 Alprafenone is a Commodity code covering specific pharmaceutical active ingredients purchased by state and local health care and emergency response agencies. State and local governments buy alprafenone and related injectable medications under this code primarily for emergency medical services, hospital pharmacy programs, and state health benefit programs. The City of Tampa Fire Rescue, Texas HHS Commission pharmacy benefit operations, and cooperative purchasing alliances such as MMCAP are the principal issuing bodies visible in recent activity, representing municipal emergency response, state health agencies, and multi-state purchasing consortia. Work solicited ranges from immediate supply of specific formulations (such as epinephrine and adenosine vials for paramedic use) to longer-term pharmaceutical distribution agreements serving multiple government jurisdictions and health plans across state lines.

Recent opportunities appear primarily in Florida and Texas, with multi-state reach through Minnesota's MMCAP cooperative. The City of Tampa issued an IFB (Bid No. 26-P-00188) due April 8, 2026, for Advanced Life Support Medications including 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a one-year initial term plus optional renewals. The Texas HHS Commission issued an RFI (HHS0017013) posted April 3, 2026, to explore direct-to-manufacturer prescription fulfillment capabilities for a Therapeutic Pharmacy Initiative outside traditional pharmacy benefit manager channels. MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals due March 26, 2026, seeks manufacturers to supply identified NDC products to authorized wholesalers serving participating state and local facilities across Minnesota and Oregon through July 1, 2026, with incumbent and new vendor contracts running through June 30, 2028. All three solicitations require FDA compliance, expiration-date warranties, OSHA Safety Data Sheets, and demonstrated manufacturing or distribution capacity.